A systems biology approach to studying the molecular mechanisms of osteoblastic differentiation under cytokine combination treatment

Towards an agent-based model to simulate osseointegration in powder-bed 3D printed implant-like structures

The orthopedic industry is still searching for an efficient way to replace bone loss due to surgical procedures such as arthroplasty and limb-sparing surgery. Additive manufacturing (AM) presents an opportunity to manufacture affordable patient-specific implants. Optimization of the implant-bone interface to maximize osseointegration (bone ingrowth) has not been appropriately addressed. Mechanobiological models, suited to predict mechanical adaptation of bone, cannot be used to predict osseointegration inside implants as the implant is not exposed to any mechanical loading until it is fully accepted by the host body. Biological models relying on partial differential equations based on continuum approximation are not well-suited to predict the discrete phenomenon of osseointegration. This study proposes an agent-based modeling (ABM) approach for representing the osseointegration process for orthopedic implants produced by powder-bed additive manufacturing processes. Agent-Based Modeling (ABM) is a cellular automata based discrete computing technique that uses rule-based mathematics derived from experimental studies to simulate evolutionary phenomena. In this paper, osseointegration inside a hexagonal closed packing of AM powder particles is modeled using ABM. Cellular agents such as pre-osteoblasts and osteoblasts are realistically modeled as cubic cells. The proposed model underpredicts osseointegration at early stages but predicts osseointegration at around 21 days with sufficient accuracy when compared to the in vitro test conducted by Xue et al. in 2007.

Designing biomaterials for the delivery of RNA therapeutics to stimulate bone healing

Ribonucleic acids (small interfering RNA, microRNA, and messenger RNA) have been emerging as a promising new class of therapeutics for bone regeneration. So far, however, research has mostly focused on stability and complexation of these oligonucleotides for systemic delivery. By comparison, delivery of RNA nanocomplexes from biomaterial carriers can facilitate a spatiotemporally controlled local delivery of osteogenic oligonucleotides. This review provides an overview of the state-of-the-art in the design of biomaterials which allow for temporal and spatial control over RNA delivery. We correlate this concept of spatiotemporally controlled RNA delivery to the most relevant events that govern bone regeneration to evaluate to which extent tuning of release kinetics is required. In addition, inspired by the physiological principles of bone regeneration, potential new RNA targets are presented. Finally, considerations for clinical translation and upscaled production are summarized to stimulate the design of clinically relevant RNA-releasing biomaterials.

Development of PLGA-PEG-COOH and gelatin-based microparticles dual delivery system and E-beam sterilization effects for controlled release of BMP-2 and IGF-1

The purpose of this study was to develop a PLGA-PEG-COOH- and gelatin-based microparticles (MPs) dual delivery system for release of BMP-2 and IGF-1. We made and characterized the delivery system based on its morphology, loading capacity, Encapsulation efficiency and release kinetics. Second, we examined the effects of electron beam (EB) sterilization on BMP-2 and IGF-1 loaded MPs and their biological effects. Third, we evaluated the synergistic effect of a controlled dual release of BMP-2 and IGF-1 on osteogenesis of MSCs. Encapsulation efficiency of growth factors into gelatin and PLGA-PEG-COOH MPs are in the range of 64.78% to 76.11%. E-beam sterilized growth factor delivery systems were effective in significantly promoting osteogenesis of MSCs, although E-beam sterilization decreased the bioactivity of growth factors in MPs by approximately 22%. BMP-2 release behavior from gelatin MPs/PEG hydrogel shows a faster release (52.7%) than that of IGF-1 from the PLGA-PEG-COOH MPs/PEG hydrogel (27.3%). The results demonstrate that the gelatin and PLGA-PEG-COOH MPs based delivery system could realize temporal release of therapeutic biomolecules by incorporating different growth factors into distinct microparticles. EB sterilization was an accessible method for sterilizing growth factors loaded carriers, which could pave the way for implementing growth factor delivery in clinical applications.

FGF-2 suppresses expression of nephronectin via JNK and PI3K pathways

Nephronectin (Npnt), an extracellular matrix protein, is a ligand for integrin α8β1 and is involved in the development of various organs, such as the kidneys, bones, liver, and muscles. Previously, we found that Npnt expression was inhibited by various cytokines including transforming growth factor‐β (Tgf‐β) and oncostatin M (Osm). Fibroblast growth factor (Fgf)‐2, otherwise known as basic Fgf, also plays important roles in skeletal development and postnatal osteogenesis. In this study, Npnt expression was found to be suppressed by Fgf‐2 in MC3T3‐E1 cells, an osteoblast‐like cell line, in a dose‐ and time‐dependent manners. Furthermore, Fgf‐2‐mediated NpntmRNA suppression was shown to involve the Jun N‐terminal kinase (JNK) and phosphoinositide‐3 kinase (PI3K) pathways. Together, our results suggest that FGF‐2 suppresses Npnt gene expression via JNK and PI3K pathways.